CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates a new long-acting treatment regimen for HIV, combining lenacapavir and Islatravir. A multi-country trial will assess its effectiveness compared to standard therapy, aiming to improve adherence and reduce the burden of daily medication.
Despite tremendous/significant efforts to expand access to antiretroviral therapy (ART), in 2023 there were still 1.3 million new HIV infections worldwide and 630,00 HIV/AIDS-related deaths.
There are 39.9 million people living with HIV worldwide (PLWH), and viral suppression rates for those on ART are below the UNAIDS target of 95%.
Current ART guidelines recommend lifelong daily oral therapy which can be burdensome, and incomplete adherence risks treatment failure.
Injectable long-acting (LA)…
THE UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
THE INFECTIOUS DISEASES INSTITUTE LIMITED
Uganda, KAMPALA
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Zimbabwe, Harare
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Kenya, Eldoret
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
